PubMed Health⌕ Search

PubMed · 6220014

The T3 complex on human T lymphocytes involves four structurally distinct glycoproteins.

Abstract

Monoclonal antibodies allow for the detection of antigens which are specific for human thymus-derived lymphocytes. Among these antigens, the T3 complex is of particular interest since it is involved in several T cell functions. The main target antigen of the anti-T3 reagents is borne by a 20-kDa glycoprotein. In addition, glycoproteins of 25-28, 37, and 44 kDa are found in anti-T3 immunoprecipitates derived from surface-labeled cells. The four antigens appeared to be strongly associated with each other in detergent-containing solutions. Comparative studies of the four proteins, facilitated by the use of endo-beta-N-acetylglycosaminidase F, revealed that their polypeptide backbones have different molecular weights and pI values. Moreover, peptide maps of the 20-kDa T3 and the 25-28-kDa T3 were quite different. Metabolic labeling experiments suggested that the 25-28-kDa protein might become associated with the 20-kDa T3 antigen during biosynthesis. The 37-kDa and 44-kDa proteins could not, however, be detected and, therefore, might become associated with the 20-kDa T3 on the cell surface. Evidence has been found for the existence of a fifth member of the T3 complex, namely an unglycosylated 20-kDa T3 species.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Borst, S Alexander, J Elder, C Terhorst. 1983-04-25. The T3 complex on human T lymphocytes involves four structurally distinct glycoproteins.. https://pubmed.ncbi.nlm.nih.gov/6220014/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

ZrO₂@C-based colorimetric/photothermal dual-mode immunosensor coupled with a novel monoclonal antibody for quantification of Aspergillus ochraceus biomass.

Aspergillus ochraceus contaminates agricultural products and produces nephrotoxic, carcinogenic ochratoxin A (OTA), posing severe food safety hazards. A dual-signal lateral flow immunochromatographic assay (dLFIA) based on ZrO₂@C nanoprobes was established for quantitative detection of A. ochraceus biomass. A novel monoclonal antibody (mAb 4B4) was prepared as the capture antibody to immobilize A. ochraceus mycelial lysate antigen on the test line, and a rabbit polyclonal antibody (pAb G2801) as the detection antibody to modify ZrO₂@C composites (synthesized via UiO-66 pyrolysis) into 200 nm colorimetric/photothermal nanoprobes. This dLFIA achieved limits of detection of 0.164 μg/mL (colorimetric) and 0.517 μg/mL (photothermal). This efficient and reliable method allows quantitative analysis of A. ochraceus biomass, which is suitable for routine monitoring of fungal contamination in agro-food matrices.

Antibodies, Monoclonal↗

Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.

Lymphoproliferative disease (LPD) is a complication of congenital and acquired immunodeficiency states. There are a number of treatment options for LPD arising after haematopoietic stem cell or solid organ transplantation including reduction of immunosuppression, targeted therapies, such as the anti-CD20 monoclonal antibody, rituximab, and EBV specific cytotoxic lymphocytes. Treatment of LPD in children with congenital immunodeficiency syndromes remains unsatisfactory and is associated with a high mortality rate. We recently managed an infant found to have polymorphic LPD concurrent with X-linked severe combined immunodeficiency (SCID). Haematopoietic stem cell transplantation (HSCT) had to be deferred because of progressive LPD. Treatment with rituximab resulted in regression of the LPD following which the patient received a 5/6 HLA matched umbilical cord blood (UCB) transplant. The patient remains well 20 months following transplantation. Rituximab treatment may have a useful role in the control of LPD associated with congenital immunodeficiency prior to HSCT.

Antibodies, Monoclonal↗

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.

Opsoclonus-myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long-term neurologic outcome. We present a case of a 19-month-old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab.

Antibodies, Monoclonal↗